Tesamorelin
Also known as: Egrifta, TH9507
Primary recreational use: Fat loss
What is Tesamorelin?
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), developed to treat HIV-associated lipodystrophy by reducing visceral adipose tissue. It is FDA-approved specifically for this condition, marking it as one of the few peptides with such approval. While effectively reducing trunk fat, its use incurs the risk of increased diabetes and glucose intolerance.
Primary Benefits
Reduces visceral fat. Improves lipid profiles. Enhances body composition.
How It Works
Tesamorelin binds to GHRH receptors on pituitary somatotroph cells, stimulating the release of growth hormone (GH). This leads to increased lipolysis, primarily targeting visceral adipose tissue, while sparing subcutaneous fat. The action elevates circulating IGF-1 levels, facilitating fat loss and metabolic improvements.
Safety Tips
Precautions reported in community discussions and literature. This is not a complete list.
- 1.DON'T use if you have active cancer or history of malignancy.
- 2.DON'T exceed the prescribed dose without medical supervision.
- 3.DON'T use if you have pituitary gland disorders.
- 4.NEVER inject into the same site repeatedly without rotation.
- 5.DON'T mix with alcohol or tobacco while on treatment.
- 6.AVOID use if you are pregnant or breastfeeding.
- 7.DON'T skip regular glucose monitoring if diabetic.
- 8.NEVER purchase from non-verified sources to avoid contamination.
Use Contexts
Different purposes have different protocols, dosing, and considerations
HIV-associated lipodystrophy
strong evidenceFDA-approved indication for reducing visceral fat in HIV patients with lipodystrophy.
Evidence: FDA approval and extensive clinical trials demonstrate significant VAT reduction in HIV-associated lipodystrophy.
The following are ranges reported in published literature and community discussions. These are NOT recommendations or medical advice.
Timing: Before bed, on an empty stomach
Notes: Administered subcutaneously in the abdomen, rotating sites to prevent lipodystrophy
Community-Reported Protocols
Not recommendations: The following protocols are compiled from online communities and published literature. Pepbase does not endorse, recommend, or verify these protocols. They are provided for informational purposes only. Individual responses vary significantly. Consult a licensed medical professional before any use.
| Reported Goal | Reported Dose | Reported Frequency | Reported Route |
|---|---|---|---|
| HIV lipodystrophy | 1.4-2 mg | Once daily | Subcutaneous |
Pharmacokinetics
Reported Side Effects
This is not a complete list. Other side effects may occur.
Common
Serious / Rare
- Increased diabetes risk
- Anaphylaxis
Injection-Specific Warnings
- Rotate injection sites to prevent development of lipodystrophy
Storage
Harm Reduction Information
Quality Concerns
- Potential contamination in non-FDA approved versions
- Degradation if not stored properly
Safety Tips
- Always rotate injection sites to prevent tissue issues
- Use bacteriostatic water for reconstitution
- Start at a low dose to assess tolerance
Warning Signs to Stop
- Severe joint pain
- Allergic reactions such as hives or difficulty breathing
Seek Medical Help Immediately If
- Signs of anaphylaxis
- Severe and persistent pain or swelling at injection site
Frequently Asked Questions
Common questions about Tesamorelin
How long until I see effects?
With Tesamorelin, IGF-1 levels rise in 1-2 weeks, and visible fat reduction is typically observed between 8-12 weeks.
What time of day should I take it?
It's best to administer Tesamorelin before bed on an empty stomach to synchronize with the body's natural GH release.
How can I minimize side effects?
To minimize side effects when using Tesamorelin, ensure correct injection techniques and regular glucose monitoring, especially if you're diabetic.
Does tolerance develop?
Tolerance is not typically reported with Tesamorelin, but regular assessment and consultation with a healthcare provider are advised.
How should I store it?
Store the reconstituted Tesamorelin solution at room temperature and use it within 7 days.
Do I need to cycle it?
For FDA-approved use, cycling is not typically required, but consult your healthcare provider for off-label uses.
Reported Combinations
Compounds reported to be used alongside Tesamorelin in community discussions
Ipamorelin
Enhanced GH release
CJC-1295
Amplified growth hormone pulses
BPC-157
Improved metabolic and recovery processes
Reported Interactions
Interactions reported in literature and community discussions.
May alter glucose levels significantly.
Increases risk of adverse metabolic effects.
Potentially affects insulin sensitivity.
Reconstitution Calculator
100 units = 1 mL
Safety Tips
- Always consult a licensed medical professional for dosing and reconstitution instructions.
- Always double check your units. Mixing up mg and mcg can be very dangerous.
- Make sure to select your syringe type. U-100 and U-50 syringes have different units.
- Ensure you're not adding more BAC than your vial can hold. Most vials have maximum capacities listed.
This calculator is for informational and educational purposes only. It does not provide medical advice, dosing recommendations, or safety determinations. Reference ranges shown are compiled from publicly available sources and are not a substitute for guidance from a licensed healthcare professional.
Legal Status by Region
Regulatory status varies by country
USA
Prescription only
UK
Prescription only
EU
Prescription only
Australia
Not specified
Canada
Prescription only
Explore More Research
Browse our database of peptide research information compiled from published literature and community sources.
Citations
Last updated: October 1, 2023